Literature DB >> 12431862

Plasma concentrations of neuroactive steroids before and after repetitive transcranial magnetic stimulation (rTMS) in major depression.

Frank Padberg1, Flavia di Michele, Peter Zwanzger, Elena Romeo, Giorgio Bernardi, Cornelius Schüle, Thomas C Baghai, Robin Ella, Augusto Pasini, Rainer Rupprecht.   

Abstract

There is evidence for altered levels of neuroactive steroids in major depression that normalize after successful antidepressant pharmacotherapy. Currently it is not known whether this is a general principle of clinically effective antidepressant therapy or a pharmacological effect of antidepressants. Here, we investigated whether repetitive transcranial magnetic stimulation (rTMS) may affect plasma concentrations of neuroactive steroids in a similar way as antidepressant pharmacotherapy. Progesterone, 3alpha,5alpha-tetrahydroprogesterone (3alpha,5alpha-THP), 3alpha,5beta- tetrahydroprogesterone (3alpha,5beta-THP), 3beta,5alpha-tetrahydroprogesterone (3beta, 5alpha-THP) and dehydroepiandrosterone (DHEA) were quantified in 37 medication-free patients suffering from a major depressive episode before and after 10 sessions of left prefrontal rTMS. Plasma samples were analyzed by means of a highly sensitive and specific combined gas chromatography/mass spectrometry analysis. There was a significant reduction of depressive symptoms after rTMS. However, plasma concentrations of neuroactive steroids were not affected by rTMS and not related to clinical response. Clinical improvement after extended daily treatment with rTMS is not accompanied by changes in neuroactive steroid levels. Changes in neuroactive steroid levels after antidepressant pharmacotherapy more likely reflect specific pharmacological effects of antidepressant drugs and are not necessary for the amelioration of depressive symptoms.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12431862     DOI: 10.1016/S0893-133X(02)00355-X

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  16 in total

1.  The GABAergic deficit hypothesis of major depressive disorder.

Authors:  B Luscher; Q Shen; N Sahir
Journal:  Mol Psychiatry       Date:  2010-11-16       Impact factor: 15.992

2.  Replication of Epigenetic Postpartum Depression Biomarkers and Variation with Hormone Levels.

Authors:  Lauren Osborne; Makena Clive; Mary Kimmel; Fiona Gispen; Jerry Guintivano; Tori Brown; Olivia Cox; Jennifer Judy; Samantha Meilman; Aviva Braier; Matthias W Beckmann; Johannes Kornhuber; Peter A Fasching; Fernando Goes; Jennifer L Payne; Elisabeth B Binder; Zachary Kaminsky
Journal:  Neuropsychopharmacology       Date:  2015-10-27       Impact factor: 7.853

Review 3.  Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?

Authors:  Abdulmaged M Traish; Roberto Cosimo Melcangi; Marco Bortolato; Luis M Garcia-Segura; Michael Zitzmann
Journal:  Rev Endocr Metab Disord       Date:  2015-09       Impact factor: 6.514

4.  5α-reductase type I expression is downregulated in the prefrontal cortex/Brodmann's area 9 (BA9) of depressed patients.

Authors:  Roberto Carlos Agis-Balboa; Alessandro Guidotti; Graziano Pinna
Journal:  Psychopharmacology (Berl)       Date:  2014-04-30       Impact factor: 4.530

Review 5.  Transcranial Magnetic Stimulation : A New Therapeutic Tool in Psychiatry.

Authors:  A A Pawar; D Saldanha; S Chaudhury; Vssr Ryali; K Srivastava
Journal:  Med J Armed Forces India       Date:  2011-07-21

6.  Lower allopregnanolone during pregnancy predicts postpartum depression: An exploratory study.

Authors:  Lauren M Osborne; Fiona Gispen; Abanti Sanyal; Gayane Yenokyan; Samantha Meilman; Jennifer L Payne
Journal:  Psychoneuroendocrinology       Date:  2017-02-16       Impact factor: 4.905

7.  Neuropsychopharmacological properties of neuroactive steroids in depression and anxiety disorders.

Authors:  Daniela Eser; Cornelius Schüle; Elena Romeo; Thomas C Baghai; Flavia di Michele; Augusto Pasini; Peter Zwanzger; Frank Padberg; Rainer Rupprecht
Journal:  Psychopharmacology (Berl)       Date:  2005-10-25       Impact factor: 4.530

Review 8.  Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research.

Authors:  Simone Rossi; Mark Hallett; Paolo M Rossini; Alvaro Pascual-Leone
Journal:  Clin Neurophysiol       Date:  2009-10-14       Impact factor: 3.708

Review 9.  Repetitive transcranial magnetic stimulation : does it have potential in the treatment of depression?

Authors:  Frank Padberg; Hans-Jürgen Möller
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

10.  Neuroactive steroids after estrogen exposure in depressed postmenopausal women treated with sertraline and asymptomatic postmenopausal women.

Authors:  Melinda L Morgan; Andrea J Rapkin; Giovanni Biggio; Mariangela Serra; Maria Giuseppina Pisu; Natalie Rasgon
Journal:  Arch Womens Ment Health       Date:  2009-09-03       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.